R&D Policy
Combining applied research and basic research, integrating independent innovation with technology introduction, consociating technical means with capital means

Three industrialized technological platforms
Large scale bioreactor cultivation technology platform, combination vaccine key technology platform, humanized monoclonal antibody technology platform
Adhering to the corporate philosophy of "All for health, health for all", the company takes promoting the development of public health and fulfilling the social responsibility of disease prevention as the main purpose, builds a platform for biopharmaceutical innovation and industrialization development, improves research and development efficiency, develops innovative products, and continuously meets people's growing needs for a better life. At present, the company has initially formed a benign development situation of "some products at pre-research stage, some products under development and some products in production", "R&D supports industrialization, and industrialization feeds back R&D".

WIBP is committed to the development of biopharmaceutical industry in the spirit of unity, enterprise, pragmatism and innovation, and strives to make due contributions to human health..

All the existing production lines for the main products have obtained the "GMP Certificate" issued by the regulatory authorities, with complete equipment and facilities, advanced technical level and first-class product quality.

73persons

Research team of 73 persons

119innovations

119 successful innovations

3major cooperation mechanisms

Establish 3 major global cooperation mechanisms